7 June 2023 - NICE has published final evidence based recommendations on the use of bulevirtide (Hepcludex) for the treatment of adults with chronic hepatitis D.

Bulevirtide acetate is recommended as an option for the treatment of adults with chronic hepatitis D with compensated liver disease only if:

• There is evidence of significant fibrosis (METAVIR stage F2 or above or Ishak stage 3 or above)
• Their hepatitis has not responded to peginterferon alfa‑2a or they cannot have interferon-based therapy

Read NICE technology appraisal guidance